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Abstract
Purpose A male infant developed generalized rash, intestinal
inflammation and severe infections including persistent cyto-
megalovirus. Family history was negative, T cell receptor exci-
sion circles were normal, and engraftment of maternal cells was
absent. No defects were found in multiple genes associated with
severe combined immunodeficiency. A 9/10 HLA matched un-
related hematopoietic cell transplant (HCT) led to mixed chime-
rism with clinical resolution. We sought an underlying cause for
this patient’s immune deficiency and dysregulation.
Methods Clinical and laboratory features were reviewed.
Whole exome sequencing and analysis of genomic DNA from
the patient, parents and 2 unaffected siblings was performed,
revealing 2MALT1 variants. With a host-specific HLA-C an-
tibody, we assessed MALT1 expression and function in the
patient’s post-HCT autologous and donor lymphocytes. Wild
typeMALT1 cDNAwas added to transformed autologous pa-
tient B cells to assess functional correction.
Results The patient had compound heterozygous DNA vari-
ants affecting exon 10 ofMALT1 (isoform a, NM_006785.3),
a maternally inherited splice acceptor c.1019-2A>G, and a de
novo deletion of c.1059C leading to a frameshift and prema-
ture termination. Autologous lymphocytes failed to express
MALT1 and lacked NF-κB signaling dependent upon the
CARMA1, BCL-10 and MALT1 signalosome. Transduction
with wild typeMALT1 cDNA corrected the observed defects.
Conclusions Our nonconsanguineous patient with early onset
profound combined immunodeficiency and immune dysregu-
lation due to compound heterozygous MALT1 mutations ex-
tends the clinical and immunologic phenotype reported in 2
prior families. Clinical cure was achieved with mixed chime-
rism after nonmyeloablative conditioning and HCT.
Keywords BCL10 . bonemarrow transplant/hematopoietic
cell transplant . CARD11 . CARMA1 . combined
immunodeficiency (CID) . erythroderma . immune
dysregulation
Introduction
Identification of the genetic causes of human immunodefi-
ciencies has revealed the roles of many factors critical for
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human lymphocyte development and function. Combined im-
munodeficiencies (CIDs) listed by the IUIS Expert Committee
on Primary Immunodeficiencies [1], include a wide spectrum
of gene defects underlying susceptibility to bacterial, viral and
fungal infections. The most profound of these, collectively
termed severe combined immunodeficiency (SCID), are dis-
orders with few to absent autologous T cells and absent cellu-
lar and humoral immune function [1–4]. In contrast, many
CID gene defects do not abrogate development or release into
the periphery of T and B cells, but instead disrupt pathways
critical for their effector and regulatory roles; examples are
ORAI-I, STIM-1 [5], and MHC class II deficiency [6]. While
over 14 different SCID genes are known [7], many patients
with CID without T cell lymphopenia have as yet unidentified
genetic defects. Whole exome sequencing (WES) may identi-
fy molecular causes of CID.
Studies in knockout mice and human malignancies and im-
munodeficiencies have delineated the intracellular signaling
pathways activated by engagement of lymphocyte antigen re-
ceptors and G-protein coupled receptors [8]. NF-κB, a central
mediator of activation signals, translocates from the cytoplasm
into the nucleus to initiate transcription of genes that bring
about lymphocyte maturation, activation and proliferation [9].
NF-κB activation and signaling is in turn controlled bymultiple
mechanisms, one of which is the signalosome formed from
assembly of CARMA1 (also called CARD11), BCL-10 and
MALT1 into the “CBM” signaling complex [10, 11]. While
the precise molecular mechanisms are still not completely clear,
stimulation through the Tcell and B cell receptors causes phos-
phorylation of CARMA1, recruitment ofMALT1 and BCL-10,
and oligomerization of components of the CBM complex
[12–14]. This in turn activates the IκB kinase complex through
TNF receptor-associated factor 6 (TRAF6)-mediated
ubiquitination of NF-κB essential modulator (NEMO)
[15–17], leading to phosphorylation and proteasomal degrada-
tion of the inhibitor IκBα and release of NF-κB. Thus, it is not
surprising that defects in NEMO, CARMA1 and MALT1 have
been found to cause human CID [18–23].
We describe a new patient in whom CID and immune dys-
regulation due to MALT1 compound heterozygous mutations
was successfully treated by allogeneic hematopoietic cell
transplantation (HCT). This case in a non-consanguineous
family, combined with 2 prior reports [22–24], broadens the




After informed consent, as approved by the University of Cal-
ifornia San Francisco Committee on Human Research, the
patient, his parents and 2 healthy siblings were studied with
whole exome sequencing and immunological assessments.
DNA Studies
Genomic DNA from the patient, obtained prior to HCT,
and from his parents and siblings was subjected to
WES. Analysis tools were similar to [25], with modifi-
cations detailed in the Supplementary methods. DNA
variants were confirmed by Sanger sequencing. With
parental consent, residual dried blood spots obtained in
the newborn nursery were recovered from the California
Department of Public Health Newborn Screening Pro-
gram, and T cell receptor excision circles (TRECs) were
analyzed as described [26].
Cell Separations and Reagents
After HCT from an unrelated donor differing at a single
HLA-C locus, the patient developed mixed chimerism of
the hematopoietic system. Patient alleles were HLA-C *08:01,
*03:04; donor alleles were *08:01, *07:02. Staining cells with
monoclonal human IgM antibody (clone ID: TRA2G9)
recognizing antigens encoded by C*01/*03/*04:01/
*14:02, but not C*07/*08 [27–29], followed by PE-an-
ti-human IgM (clone MHM-88), permitted separation of au-
tologous patient lymphocytes from those of the donor by flow
cytometry. For specific antibodies see Supplementary
methods.
PCR and Western Blotting
RNA was isolated from sorted autologous patient PBMCs
obtained post-HCT (RNeasy kit, Qiagen), and expression of
MALT1 transcripts (primers in Suppl Table 1) was detected by
PCR (Superscript III system, Life Technologies) followed by
Sanger sequencing. The sorted cells were also lysed with 1 %
NP-40 and analyzed byWestern blotting using antibodies rec-
ognizing MALT1 (EP603Y, Abcam) and BCL-10 (H-197,
Santa Cruz Biotechnologies).
Intracellular Signaling Assays
For phosphorylation assays PBMCs or Epstein-Barr virus
(EBV) transformed B cells were stimulated with 400 nM
PMA and 250 ng/ml ionomycin at 37 °C, for 10 min. For
cytokine assays PBMCs were stimulated for 6 h with PMA
plus ionomycin; 200 ng/ml superantigen staphylococcal
enterotoxin E (SEE, Toxin Technology, Inc.) plus 4 ug/
ml anti-CD28 clone 9.3; or 1:500 anti-CD3 clone Leu-4
ascites plus 4 ug/ml anti-CD28. The cells were then
fixed, permeabilized (Invitrogen Solutions A and B,
Life Technologies) and incubated with either phospho-
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specific unconjugated antibodies followed by anti-rabbit-
PE, or anti-mouse-FITC labeled secondary antibodies, or
antibodies against IL-2 or IFN-γ. Fluorescent antibodies
to relevant surface markers were included.
Fig. 1 a, Skin lesions, showing (i) facial erythroderma (ii) dorsal trunk
and (iii) close-up with linear distribution of lesions corresponding to
excoriations. b, Schematic representation of MALT1 protein (isoform a,
NP_006776.1), illustrating death domain, 3 immunoglobulin (Ig)-like
domains, and paracaspase domain [30]. Mutations are shown for our
patient (black) and prior homozygous cases (blue) [22, 23]. c, Browser
view of patient stacked DNA sequence tracks, demonstrating >30X
coverage with individual reads homozygous for either the splice
disrupting variant c.1019-2A>G or the single nucleotide deletion
cDNA c.1060delC (the former also present in maternal DNA, not
shown) (ClinVar number SCV000196510). Colored blocks, non-reference
nucleotides; black blocks, deleted nucleotides. Below, genomic sequence of
MALT1 exon 10 (isoform a, NM_006785.3) and protein translation with
reference sequence (black) and de novo deleted sequence (red)
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Lentivirus Transduction
MALT1 cDNA (Genecopia) was ligated into lentiviral vector
MP-283: pSicoR-BstXI-EF1a-puro-T2A-mCherry, (kindly
provided by Michael McManus, Lentiviral RNAi Core,
UCSF). MP-283-MALT1 lentiviral supernatant prepared by
transient transfection of 293 cells in DMEM medium with
10 % fetal calf serum (FCS) was used to transduce EBV cells
in plates pre-coated with Rectronectin (Takara, Japan). After
two 24 h infections, the EBV cells were washed and expanded
in RPMI 1640 medium with GlutaMax (Invitrogen), 20 %
FCS, penicillin, and streptomicin. MP-283 lentivirus prepared
as above without the insert was used in parallel. Transduced
cells were detected by mCherry fluorescence.
Results
Patient History
The infant, born at term to non-consanguineous parents with
negative family history, developed blood-streaked diarrhea and
a desquamating, erythematous pruritic rash, the latter evolving
into firm erythematous papules affecting trunk, palms and soles
(Fig. 1a, Table 1). There were no indications of environmental
atopy; IgE was undetectable, and steroids were ineffective. Skin
biopsies showed perivascular lymphocytic infiltration in the der-
mis. Following monthly otitis media infections, an immune
workup showed expansion of CD4 and CD8 T cell populations
with high proportions of naïve CD45RA T cells, but impaired
in vitro proliferative responses (Tables 1 and 2). Maternal T cell
engraftment was absent, and the newborn dried blood spot, re-
trieved from the time of the patient’s birth, had 627 Tcell receptor
excision circles (TRECs)/μL (normal >40). B and NK cells were
present, but low immunoglobulin levels and absent antibody re-
sponses to vaccines necessitated immunoglobulin infusions. The
patient experienced poor weight growth, stomatitis, oral thrush,
RSV bronchiolitis, and CMV viremia and CMV pneumonitis.
At 18 months of age, following non-ablative conditioning
with 120 mg/kg cyclophosphamide, 140 mg/m2 melphalan and
8 mg/kg rabbit anti-thymocyte globulin, the patient received
peripheral mobilized CD34-selected cells from a 9 of 10 HLA
antigen-matched unrelated donor (differing at one HLA-C lo-
cus). The patient received 4.85×106 CD34 cells/kg and 14.72×
106 CD3 cells/kg. Graft versus host disease (GVHD) prophy-
laxis included methotrexate and cyclosporine, and no GVHD
was observed. The patient’s rash resolved within 4 weeks and
did not return. Donor T cell function was established by
5 months post-HCT. However, diarrhea and CMV viremia,
refractory to gancyclovir and foscarnet treatment, continued
until both resolved promptly following infusion 12 months
post-HCT of donor T cells that had been pulsed in vitro with
CMV peptide and expanded. Immunoglobulin replacement has
been given post-HCT, but donor B cell chimerism, IgA, IgM
and anti-A IgM isohemagglutinins are now detectable.
Identification of Mutations in MALT1
Sequencing of a comprehensive panel of known SCID genes
revealed no mutations. To search for disease-causing variants,
Table 1 Clinical course, indicating infections, autoimmune manifestations, treatments (in italics) and times at which samples were obtained for study
Age Clinical manifestation
1–3 months Bloody stool, erythroderma (later biopsy showing lymphocyte infiltration)
9 months Poor growth (<5 % weight, 5 % height), hospitalization for prolonged fever, presumed bacterial
infections responding to systemic antibiotics; S. aureus superinfection of rash
10 months IgG infusions instituted
13 months Thrush, candida esophagitis
Continuous antibiotic prophylaxis started
DNA isolated from PBMCs, later used for whole exome sequencing
15 months Persistent CMV >3,000 copies by PCR from blood, lung washings despite gancyclovir and foscarnet
treatment; ground glass pneumonitis; self limited RSV bronchiolitis; diarrhea with C. difficile
18 months Hematopoietic cell transplant from 9/10 HLA matched unrelated donor
19 months Rash resolved, donor T cells detected; no graft vs. host disease
23 months Graft vs. host disease prophylaxis discontinued
Lymphocyte proliferation to PHA >50 % normal, persistent CMV viremia 1,500 copies
PBMCs isolated, separated into autologous patient and donor populations for in vitro functional studies
28 months Antibiotic prophylaxis discontinued
30 months Donor T cell infusion for persistent CMV viremia
CMV viremia resolved, gaining weight (25 % for age)
6 years Donor B cell function detected with normal IgM and IgA, positive IgM isohemagglutinin


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































140 J Clin Immunol (2015) 35:135–146
WES was performed on genomic DNA from the patient (pre-
HCT) and nuclear family, with analysis under the hypothesis
of an autosomal or X-linked recessive single gene disorder.
The patient was a compound heterozygote with 2 non-
synonymous variants affecting MALT1 exon 10 (isoform a,
NM _ 0 0 6 7 8 5 . 3 ) ( F i g . 1 b a n d c ) ( C l i n Va r
number SCV000196510) [30]. As shown, the variants were
sufficiently close to one another to determine that they resided
on opposite haplotypes; all sequence reads showed one or the
other, but not both variants: a splice acceptor defect, cDNA
c.1019-2A >G (also in maternal DNA); and a single nucleotide
deletion, cDNA c.1060delC, leading to a frameshift within the
MALT1 paracaspase domain and truncation after 18 missense
codons, p.Y353fs*18 (not in either parent or siblings, thus de
novo in the patient).
Patient Mixed Donor Chimerism
Following HCT, mixed chimerism in the blood was established
with 11.2% of peripheral blood nucleated cells and 16.6% of T
cells being donor derived (Table 2). Using the TRA2G9 mono-
clonal antibody to label the patient’s, but not the donor’s, HLA-
C antigens, the autologous PBMCs were distinguished by flow
cytometry (Fig. 2a), showing 15.5 % donor T cells and 3.4 %
donor B cells, in agreement with clinical determinations. Only
0.25 % of the donor CD4 T cells were naïve CD45RA positive
cells. Pre-HCT patient CD4+ CD25+ regulatory T cells (Tregs)
and FOXP3 expressing Tcells were low, but were restored after
HCT (Table 2). Almost all Tregs and all active Tregs in the
patient’s PBMCs were donor-derived (Fig. 2b).
Expression of MALT1 mRNA and MALT1 Protein
Autologous, TRA2G9 antibody-positive patient lymphocyte
subsets were sorted from post-HCT patient PBMCs; MALT1
cDNA was prepared from these cells and from blood samples
from the mother and a healthy control. The wild type MALT1
exon 10 contains an even multiple of 3 nucleotides encoding a
predicted nuclear export signal and allowing for the possibility of
in-frame exon skipping. Indeed, short cDNA amplicons with
exon 9 joined to exon 11 were detected from patient and mother,
but not controls, using the internal primers listed in Supplemen-
tary Table 1. However, larger amplicons lacking exon 10 were
never observed, despite robust amplification of wild type cDNA
including exon 10 from controls and even from the patient in
trace amounts (not shown). No cDNA from the patient
c.1060delC allele could be amplified, consistent with nonsense-
mediated decay of mRNA from this early truncation allele.
Whole cell lysates from autologous, sorted patient PBMCs
had no detectable MALT1 protein, while maternal heterozy-
gous cellular MALT1 levels were reduced compared to the
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Functional Consequences of MALT1 Mutations in PBMCs
Phosphorylation of NF-κB and degradation of IκB following
stimulation were analyzed to indicate the status of the CBM
signalosome in PBMCs from the patient, his mother and a
control. The patient’s autologous cells, identified by staining
with the TRA2G9 antibody, were unable to phosphorylate
NF-κB or degrade IκB (Fig. 3a, left and right panels, respec-
tively), while cells from the mother and control cells demon-
strated equivalent levels of NF-κB phosphorylation and IκB
degradation in naïve and memory Tcells as well as B cells. As
noted above, too few donor-derived naïve T cells were detect-
ed in the patient’s blood to analyze. Phosphorylation of Erk,
P38 and S6, each independent of the CBM signalosome, was
intact in autologous patient cells, demonstrating selectivity of
the MALT1 defect (Suppl Figure 1).
We also examined downstream effects of MALT1-
dependent NF-κB signaling. After activation with PMA and
ionomycin, donor-derived memory Tcells and naïve and mem-
ory T cells from the mother and control had abundant IL-2 and
IFN-γ, but the patient’s autologous, MALT1-defective T cells
had little of either cytokine (Fig. 3b). Similar results were ob-
served in PBMCs stimulated by the superantigen SEE or anti-
CD3 plus anti-CD28 (Suppl Figure 2).
Reconstitution of Impaired NF-κB Signaling in MALT1
Defective Epstein-Barr Virus Transformed B Cell Lines
A pure TRA2G9-positive MALT1 defective sub-line was ex-
panded from sorted patient EBV cells. This and a control EBV
line were analyzed at rest and following stimulation, showing
the same inability as Tcells to phosphorylate NF-κB or degrade
IκB in response to PMA and ionomycin (Fig. 3c and not
shown). To conclusively implicate MALT1 in the functional
deficits observed in CBM complex formation and downstream
signaling, patient EBV cells were transduced with MP283 len-
tiviruses expressing mCherry alone or WTMALT1 cDNA and
mCherry. While the former had no effect (Fig. 3c, middle
panels), the vector restoring MALT1 normalized both NF-κB
phosphorylation and IκB destruction (Fig. 3c, bottom panels).
Fig. 2 a, Flow cytometry of PBMCs from the patient, mother and a
healthy control, using the TRA2G9 antibody to separate patient
autologous cells expressing HLA-C*01/*03/*04:01/*14:02 from donor-
derived cells expressing *08:01, *07:02. Left panels, naïve CD4+,
CD45RA or CD4+ CD45RO+ T cells; right panels, CD19 B cells. b,
Upper panels, total Treg cells (CD25+, FoxP3+); lower panels, resting
(CD45RA+, FoxP3+) and active (CD45RA-, FoxP3+) Treg cells in
PBMCs from patient autologous and donor populations, the mother;
and a healthy control. c, MALT1 protein expression in total cell lysates
isolated from PBMCs from the patient autologous cells, maternal cells
and cells from a healthy control. Beta-actin was used as a loading control.
All data representative of 3 independent experiments
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Discussion
Our patient with profound CID and dysregulation adds to the
2 prior reports and extends our understanding of MALT1-
associated disease and its therapy [22, 23]. Like the prior cases
(Table 2), our patient had functionally impaired T and B cells
leading to recurrent bacterial and viral infections from
early life, notably with CMV, which in our patient was
not controlled by antiviral therapy and required post-
HCT donor T cell infusions for resolution. While HCT
was recently postulated as treatment for MALT1-deficient
CID [24], our report is the first of a MALT1-deficient patient
cured by HCT. Two prior siblings died in childhood and a
surviving teenager suffers significant multi-organ disease, in-
cluding T cell inflammation of the skin and bowel similar to
that in our patient.
MALT1mutant patients reported to date had variable B cell
numbers, serum immunoglobulin levels and ability to make
specific antibodies (Table 2). Immune dysregulation
consisting of prominent rash and suspected inflammatory
bowel disease was shared between our patient and the living
girl with W580S mutation [23]. In contrast to that patient,
however, ours had normal B cell numbers, no IgE elevation
and (like the deceased children with S89I mutation) absent
protective antibody production.
Our patient’s MALT1 compound heterozygous mutations
resulted in undetectable protein andMALT1 function. As with
the previous reports, after introduction of wild type MALT1
cDNA, our patient’s mutant cells had MALT1 expression and
NF-κB signaling reconstituted. Our case also highlights how
MALT1 mutations may lead to immune dysregulation and
autoimmunity. After HCT, almost all Tregs and all active
Fig. 3 a, Intracellular phospho-NF-κB and IκB in gated unstimulated
(gray shading) vs. PMA and ionomycin stimulated (black line) naïve and
memory CD3+ T cells and CD19+ B cells from the patient, including
patient autologous (TRA2G9+) and donor-derived (TRA2G9-) cells; also
analyzed were cells from the mother and a healthy control. b, T cell
expression of intracellular IL-2 (y-axis) and IFN-γ (x-axis) without (left
panels) and with (right panels) PMA plus ionomycin stimulation. c,
Analysis of NF-κB phosphorylation and IκB degradation without (gray
shading) or with (black lines) stimulation with PMA and ionomycin.
Upper panels, control EBV B cells; middle panels, patient autologous
EBV B cells transduced with empty MP283 lentivirus; bottom panels,
patient autologous EBV B cells transduced with MP283-MALT1
lentivirus. All data representative of 3 independent experiments
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Tregs in our patient’s PBMCs were donor-derived (Fig. 2b),
accounting for the pre-HCT failure of autologous T cells to
control auto-reactive attack on the skin and possibly the intes-
tinal tract. The mixed chimerism exhibited by our patient post-
HCT allowed us to evaluate both wild type and MALT1 defi-
cient lymphocytes that had developed from hematopoietic
progenitors in vivo. Moreover, our patient’s disease resolved
even though he received a non-myeloablative preparative reg-
imen (due to his high risk status with ongoing CMV infection)
that did not result in a substantial circulating naïve T cell
population. Whether the donor T cells originated from limited
thymic development from CD34 progenitors vs. expanded
donor Tcells, or a combination of both, cannot be determined.
However, the patient’s successful outcome indicates that only
15% of donor Tcells were sufficient to reconstitute functional
immunity and immune regulation.
The two heterozygous mutations in our patient abrogated
MALT1 protein expression. Whereas the p.Y353fs*18 tran-
script was, as expected, degraded by nonsense-mediated
mRNA decay, full-length transcripts skipping exon 10, due
to the splice acceptor site defect, were also not detectable.
MALT1 protein normally shuttles between the cytoplasm
and nucleus with the aid of a nuclear export signal (NES1)
[31, 32] and a regulatory region for NES1 encoded in exon 10,
as well as second NES (NES2) in the C-terminal region of the
protein [33, 34]. If a transcript missing exon 10 had been
stable in our patient, the resulting protein might have been
trapped in the nucleus. However, no nuclear or cytoplasmic
protein from autologous patient cells was detected.
The high degree of consanguinity in the previously report-
ed patients may indicate that loci other thanMALT1modified
their immune phenotype as well as contributing to delayed
bone age, fractures, short stature, and dysmorphia in the sur-
viving patient and poor growth in the deceased siblings; these
features were absent in our outbred patient who had com-
pound heterozygosity at the MALT1 locus and has regained
normal weight and stature following HCT.
Malt1−/− mice have defects in TCR activation and cyto-
kine production similar to those observed in humans with
MALT1 deficiency [10, 35]. Malt1−/− mice demonstrate di-
verse B cell defects, as have humans, with NF-κB activity in B
cells reduced in one report [36], but only marginally altered
after immunoglobulin receptor engagement in another [35].
Mice deficient in CBMcomplex proteins have reduced thymic
Treg cells [37, 38], but this has not been described in mice
lacking Malt1. While the recently discovered human patients
with CARD11 mutations had Treg deficiency, similar to the
mouse model [20, 21], and Tregs were either normal or not
studied in the previously described patients withMALT1 mu-
tations, our patient’s autologous PBMCs had nearly absent
Tregs and very low levels of Foxp3 expression. Thus, al-
though Malt1 appears not to be required for development of
Tregs in mice, it may be important in humans, in keeping with
our patient’s resolution of dysregulated immune phenotypes
following HCT that provided donor-derived Tregs.
When determining the underlying cause of immune defi-
ciencies without lymphopenia and with normal TREC num-
bers, signaling molecules downstream of the antigen receptors
have become candidates for analysis. As shown by our patient
and others with defects in MALT1, as well as patients lacking
CARMA1, NF-κB essential modulator, and IKK2 (IKBKB)
[39], proteins important in antigen receptor and NF-κB sig-
naling should be investigated in patients with combined
immunodeficiency.
Conclusions
MALT1 deficiency can cause infantile combined immunode-
ficiency and immune dysregulation without T cell lymphope-
nia, but with impaired lymphocyte signaling through NF-κB,
failure to generate memory and regulatory T cells, and
hypogammaglobulinemia. Hematopoietic cell transplantation
can be curative.
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